Julian S. Gangolli
Julian S. Gangolli has served as a director since July 2016. He is President, North America of GW Pharmaceuticals Inc., spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd. in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England.